TitleSOX4 enables oncogenic survival signals in acute lymphoblastic leukemia.
Publication TypeJournal Article
Year of Publication2013
AuthorsRamezani-Rad, Parham, Geng Huimin, Hurtz Christian, Chan Lai N., Chen Zhengshan, Jumaa Hassan, Melnick Ari, Paietta Elisabeth, Carroll William L., Willman Cheryl L., Lefebvre Véronique, and Müschen Markus
JournalBlood
Volume121
Issue1
Pagination148-55
Date Published2013 Jan 03
ISSN1528-0020
KeywordsAnimals, B-Lymphocytes, Benzamides, Cell Survival, Child, DNA Methylation, Gene Expression Regulation, Leukemic, Humans, Imatinib Mesylate, Kaplan-Meier Estimate, Mice, Mice, Inbred NOD, Mice, SCID, Multicenter Studies as Topic, Neoplasm Proteins, Piperazines, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Promoter Regions, Genetic, Proportional Hazards Models, Protein Kinase Inhibitors, Pyrimidines, Radiation Chimera, Randomized Controlled Trials as Topic, Signal Transduction, SOXC Transcription Factors, Tumor Cells, Cultured, Tumor Stem Cell Assay
Abstract

<p>The Sox4 transcription factor mediates early B-cell differentiation. Compared with normal pre-B cells, SOX4 promoter regions in Ph(+) ALL cells are significantly hypomethylated. Loss and gain-of-function experiments identified Sox4 as a critical activator of PI3K/AKT and MAPK signaling in ALL cells. ChIP experiments confirmed that SOX4 binds to and transcriptionally activates promoters of multiple components within the PI3K/AKT and MAPK signaling pathways. Cre-mediated deletion of Sox4 had little effect on normal pre-B cells but compromised proliferation and viability of leukemia cells, which was rescued by BCL2L1 and constitutively active AKT and p110 PI3K. Consistent with these findings, high levels of SOX4 expression in ALL cells at the time of diagnosis predicted poor outcome in a pediatric clinical trial (COG P9906). Collectively, these studies identify SOX4 as a central mediator of oncogenic PI3K/AKT and MAPK signaling in ALL.</p>

DOI10.1182/blood-2012-05-428938
Alternate JournalBlood
PubMed ID23152540
PubMed Central IDPMC3538327
Grant ListR01 AR054153 / AR / NIAMS NIH HHS / United States
R01AR54153 / AR / NIAMS NIH HHS / United States
R21 CA152497 / CA / NCI NIH HHS / United States
R21CA152497 / CA / NCI NIH HHS / United States
R01 CA157644 / CA / NCI NIH HHS / United States
R01 CA172558 / CA / NCI NIH HHS / United States
U01 CA157937 / CA / NCI NIH HHS / United States
R01CA169458 / CA / NCI NIH HHS / United States
U24 CA114737 / CA / NCI NIH HHS / United States
R01CA139032 / CA / NCI NIH HHS / United States
R01 CA137060 / CA / NCI NIH HHS / United States
R01CA137060 / CA / NCI NIH HHS / United States
R01 CA169458 / CA / NCI NIH HHS / United States
R01 CA139032 / CA / NCI NIH HHS / United States
R01CA157644 / CA / NCI NIH HHS / United States